Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation

• Main Authors: A. S. Kolbin (Author), A. A. Kurylev (Author), Yu. E. Balykina (Author), M. A. Proskurin (Author)
• Format: Knjiga
• Izdano: Izdatelstvo OKI, 2018-05-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Aim. To perform health-economic evaluation of vemurafenib in comparison to dabrafenib in patients with metastatic or unresectable melanoma with BRAF V600 mutation in Russia from the healthcare system perspective. Materials and methods. Mathematical modelling and cost effectiveness analysis with cost...